Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares (CANF)
Stock · AMEX · Health Care
$1.79as of 10/16/2026
Price chart
Active signals
CANF Signal Track Record
How signals performed across all stocks →What CANF's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band BreakdownActive now | 22 | -4.6% | 41% | October 8, 2026 |
| Bollinger Band Breakout | 22 | -14.3% | 23% | August 6, 2026 |
| Volume Spike | 10 | -11.3% | 40% | September 2, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -7.5% | 33% | October 28, 2024 |
| Any 20-session window (baseline) | -6.1% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CANF
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial fo…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 5
- Website
- www.canfite.com/
Fundamentals
- 1-day range
- $1.85$1.93
- Market cap
- $7.63M
- P/E (trailing)
- —
- P/E (forward)
- -2.03
- EPS (trailing)
- $-10.30
- Dividend yield
- —
- Beta
- -0.64
- Avg. volume
- 366.3K
- Dividend pay date
- May 10, 2019
Forecasts
1 analyst ratings
Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares Competitors
Chosen by industry and closest market cap.
- CANFCan-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares$1.76▼ 4.86%Market cap $7.63MP/E —$299$9,000,000
- CNSPCNS Pharmaceuticals Inc. Common Stock$4.85▼ 6.30%Market cap $7.65MP/E —$1.9$10.54
- PCSAProcessa Pharmaceuticals Inc. Common Stock$1.69▲ 0.60%Market cap $7.65MP/E 3.31$1.04$11
- MBRXMoleculin Biotech Inc. Common Stock$0.28▼ 24.32%Market cap $7.50MP/E —$0.1614$15.75
- MTVAMetaVia Inc. Common Stock$1.26▼ 8.03%Market cap $7.49MP/E —$0.9661$14.85
- BOLTBolt Biotherapeutics Inc. Common Stock$4▼ 5.66%Market cap $7.44MP/E —$3.1$7.2
- APREAprea Therapeutics Inc. Common stock$0.584▼ 5.50%Market cap $7.83MP/E —$0.548$1.69
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CANF Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares | $7.63M | — | $1.76 | ▼ 4.86% | $299$9,000,000 |
| CNSP CNS Pharmaceuticals Inc. Common Stock | $7.65M | — | $4.85 | ▼ 6.30% | $1.9$10.54 |
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.65M | 3.31 | $1.69 | ▲ 0.60% | $1.04$11 |
| MBRX Moleculin Biotech Inc. Common Stock | $7.50M | — | $0.28 | ▼ 24.32% | $0.1614$15.75 |
| MTVA MetaVia Inc. Common Stock | $7.49M | — | $1.26 | ▼ 8.03% | $0.9661$14.85 |
| BOLT Bolt Biotherapeutics Inc. Common Stock | $7.44M | — | $4 | ▼ 5.66% | $3.1$7.2 |
| APRE Aprea Therapeutics Inc. Common stock | $7.83M | — | $0.584 | ▼ 5.50% | $0.548$1.69 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Farbstein Motti · June 4, 2026 · Grant24.0K
- Fishman Pnina · June 4, 2026 · Grant24.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 138.3K
- Total value held
- $328.7K
- Institutional holders
- 14
- Unknown42.6K
- Unknown34.1K
- Unknown20.9K
- Unknown19.4K
- Unknown12.9K
- Unknown5.5K
- Unknown2.2K
- Unknown450
- Unknown150
- Unknown125
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
CANF files prospectus for ~6.6M share offering
Can-Fite Biopharma has filed a prospectus for an offering of approximately 6.6 million ordinary shares on behalf of existing shareholders. The filing signals a planned secondary sale that may increase the number of shares available in the market. Shares are currently near the lower end of recent price action, with an RSI around 30, indicating limited upside pressure from the news.
CANF files prospectus for ~6.6M share offering. Can-Fite Biopharma has filed a prospectus for an offering of approximately 6.6 million ordinary shares on behalf of existing shareholders. The filing signals a planned secondary sale that may increase the number of shares available in the market. Shares are currently near the lower end of recent price action, with an RSI around 30, indicating limited upside pressure from the news.